Cardio-oncology is a rapidly growing field aimed at minimizing the effects of cardiovascular morbidity and mortality in cancer survivors. To meet this aim, patients are assessed at baseline to define their risk of cardiotoxicity and then followed closely during and after chemotherapy to assess for early signs or symptoms of cardiovascular disease. Cardiac imaging, and in particular, transthoracic echocardiography, plays an essential role in the baseline assessment and serial follow-up of cardio-oncology patients. The objectives of this paper are to review the mechanisms of cardiotoxicity of several common chemotherapeutic agents associated with an increased risk for left ventricular systolic dysfunction and to outline recommendations regarding the baseline assessment and serial follow-up of cardio-oncology patients with a focus on the role of echocardiography.
Carolyn M Larsen and Sharon L Mulvagh
Stella Kyung, Alan Brett Goldberg, Steven Feinstein, Stephanie Wilson, Sharon L. Mulvagh and Petros Nihoyannopulos
The 34th annual Advances in Contrast Ultrasound (ACU) International Bubble Conference convened in Chicago, IL on September 5-6, 2019 to feature new directions of research, pre-clinical and first-in-man clinical trials and novel clinical applications highlighting the diversity and utility of contrast enhanced ultrasound (CEUS). An expert group comprised of clinicians, engineers, basic scientists, government officials, attorneys, and industry partners convened to collaborate on cutting-edge ultrasound enhancement technology. Utilizing this information, the International Contrast Ultrasound Society (ICUS) continues to have cause to advocate for the safe and appropriate use of CEUS with expanding indications and applications.